Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01458288 · FLOW

Participant flow

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease · Source last updated 2021-04-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    TG-0054 (3.14 mg/kg) TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
    id
    FG000
    title
    TG-0054 (3.14 mg/kg TG-0054 Administrated Via 15-min IV Infus)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Duration of the Study: This study will consist of a 14-day screening period, a 2- to 11-day treatment period, and a 7-day follow-up period. Number of Patients: Approximately 12 treatment evaluable patients will be enrolled in this study. Study Location: Single site in US.
Complete source fields
groups
  1. description
    TG-0054 (3.14 mg/kg) TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
    id
    FG000
    title
    TG-0054 (3.14 mg/kg TG-0054 Administrated Via 15-min IV Infus)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Duration of the Study: This study will consist of a 14-day screening period, a 2- to 11-day treatment period, and a 7-day follow-up period. Number of Patients: Approximately 12 treatment evaluable patients will be enrolled in this study. Study Location: Single site in US.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice